author_facet Mancikova, Veronika
Montero-Conde, Cristina
Perales-Paton, Javier
Fernandez, Agustin
Santacana, María
Jodkowska, Karolina
Inglada-Pérez, Lucia
Castelblanco, Esmeralda
Borrego, Salud
Encinas, Mario
Matias-Guiu, Xavier
Fraga, Mario
Robledo, Mercedes
Mancikova, Veronika
Montero-Conde, Cristina
Perales-Paton, Javier
Fernandez, Agustin
Santacana, María
Jodkowska, Karolina
Inglada-Pérez, Lucia
Castelblanco, Esmeralda
Borrego, Salud
Encinas, Mario
Matias-Guiu, Xavier
Fraga, Mario
Robledo, Mercedes
author Mancikova, Veronika
Montero-Conde, Cristina
Perales-Paton, Javier
Fernandez, Agustin
Santacana, María
Jodkowska, Karolina
Inglada-Pérez, Lucia
Castelblanco, Esmeralda
Borrego, Salud
Encinas, Mario
Matias-Guiu, Xavier
Fraga, Mario
Robledo, Mercedes
spellingShingle Mancikova, Veronika
Montero-Conde, Cristina
Perales-Paton, Javier
Fernandez, Agustin
Santacana, María
Jodkowska, Karolina
Inglada-Pérez, Lucia
Castelblanco, Esmeralda
Borrego, Salud
Encinas, Mario
Matias-Guiu, Xavier
Fraga, Mario
Robledo, Mercedes
Clinical Cancer Research
Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Cancer Research
Oncology
author_sort mancikova, veronika
spelling Mancikova, Veronika Montero-Conde, Cristina Perales-Paton, Javier Fernandez, Agustin Santacana, María Jodkowska, Karolina Inglada-Pérez, Lucia Castelblanco, Esmeralda Borrego, Salud Encinas, Mario Matias-Guiu, Xavier Fraga, Mario Robledo, Mercedes 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-16-0947 <jats:title>Abstract</jats:title> <jats:p>Purpose: Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers, and the etiology specific to each known susceptibility mutation remains unknown. Exploiting multilayer genomic data, we focused our interest on the role of aberrant DNA methylation in MTC development.</jats:p> <jats:p>Experimental Design: We performed genome-wide DNA methylation profiling assessing more than 27,000 CpGs in the largest MTC series reported to date, comprising 48 molecularly characterized tumors. mRNA and miRNA expression data were available for 33 and 31 tumors, respectively. Two human MTC cell lines and 101 paraffin-embedded MTCs were used for validation.</jats:p> <jats:p>Results: The most distinctive methylome was observed for RETM918T-related tumors. Integration of methylation data with mRNA and miRNA expression data identified genes negatively regulated by promoter methylation. These in silico findings were confirmed in vitro for PLCB2, DKK4, MMP20, and miR-10a, -30a, and -200c. The mutation-specific aberrant methylation of PLCB2, DKK4, and MMP20 was validated in 25 independent MTCs by bisulfite pyrosequencing. The methylome and transcriptome data underscored JAK/Stat pathway involvement in RETM918T MTCs. Immunostaining [immunohistochemistry (IHC)] for the active form of signaling effector STAT3 was performed in a series of 101 MTCs. As expected, positive IHC was associated with RETM918T-bearing tumors (P &amp;lt; 0.02). Pharmacologic inhibition of STAT3 activity increased the sensitivity to vandetanib of the RETM918T-positive MTC cell line, MZ-CRC-1.</jats:p> <jats:p>Conclusions: Multilayer OMIC data analysis uncovered methylation hallmarks in genetically defined MTCs and revealed JAK/Stat signaling effector STAT3 as a potential therapeutic target for the treatment of RETM918T MTCs. Clin Cancer Res; 23(5); 1334–45. ©2016 AACR.</jats:p> Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in <i>RET</i>M918T Tumors Clinical Cancer Research
doi_str_mv 10.1158/1078-0432.ccr-16-0947
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE2LTA5NDc
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE2LTA5NDc
institution DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
imprint American Association for Cancer Research (AACR), 2017
imprint_str_mv American Association for Cancer Research (AACR), 2017
issn 1078-0432
1557-3265
issn_str_mv 1078-0432
1557-3265
language English
mega_collection American Association for Cancer Research (AACR) (CrossRef)
match_str mancikova2017multilayeromicdatainmedullarythyroidcarcinomaidentifiesthestat3pathwayasapotentialtherapeutictargetinretm918ttumors
publishDateSort 2017
publisher American Association for Cancer Research (AACR)
recordtype ai
record_format ai
series Clinical Cancer Research
source_id 49
title Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_unstemmed Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_full Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_fullStr Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_full_unstemmed Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_short Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_sort multilayer omic data in medullary thyroid carcinoma identifies the stat3 pathway as a potential therapeutic target in <i>ret</i>m918t tumors
topic Cancer Research
Oncology
url http://dx.doi.org/10.1158/1078-0432.ccr-16-0947
publishDate 2017
physical 1334-1345
description <jats:title>Abstract</jats:title> <jats:p>Purpose: Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers, and the etiology specific to each known susceptibility mutation remains unknown. Exploiting multilayer genomic data, we focused our interest on the role of aberrant DNA methylation in MTC development.</jats:p> <jats:p>Experimental Design: We performed genome-wide DNA methylation profiling assessing more than 27,000 CpGs in the largest MTC series reported to date, comprising 48 molecularly characterized tumors. mRNA and miRNA expression data were available for 33 and 31 tumors, respectively. Two human MTC cell lines and 101 paraffin-embedded MTCs were used for validation.</jats:p> <jats:p>Results: The most distinctive methylome was observed for RETM918T-related tumors. Integration of methylation data with mRNA and miRNA expression data identified genes negatively regulated by promoter methylation. These in silico findings were confirmed in vitro for PLCB2, DKK4, MMP20, and miR-10a, -30a, and -200c. The mutation-specific aberrant methylation of PLCB2, DKK4, and MMP20 was validated in 25 independent MTCs by bisulfite pyrosequencing. The methylome and transcriptome data underscored JAK/Stat pathway involvement in RETM918T MTCs. Immunostaining [immunohistochemistry (IHC)] for the active form of signaling effector STAT3 was performed in a series of 101 MTCs. As expected, positive IHC was associated with RETM918T-bearing tumors (P &amp;lt; 0.02). Pharmacologic inhibition of STAT3 activity increased the sensitivity to vandetanib of the RETM918T-positive MTC cell line, MZ-CRC-1.</jats:p> <jats:p>Conclusions: Multilayer OMIC data analysis uncovered methylation hallmarks in genetically defined MTCs and revealed JAK/Stat signaling effector STAT3 as a potential therapeutic target for the treatment of RETM918T MTCs. Clin Cancer Res; 23(5); 1334–45. ©2016 AACR.</jats:p>
container_issue 5
container_start_page 1334
container_title Clinical Cancer Research
container_volume 23
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792348155999682571
geogr_code not assigned
last_indexed 2024-03-01T18:06:42.099Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Multilayer+OMIC+Data+in+Medullary+Thyroid+Carcinoma+Identifies+the+STAT3+Pathway+as+a+Potential+Therapeutic+Target+in+RETM918T+Tumors&rft.date=2017-03-01&genre=article&issn=1557-3265&volume=23&issue=5&spage=1334&epage=1345&pages=1334-1345&jtitle=Clinical+Cancer+Research&atitle=Multilayer+OMIC+Data+in+Medullary+Thyroid+Carcinoma+Identifies+the+STAT3+Pathway+as+a+Potential+Therapeutic+Target+in+%3Ci%3ERET%3C%2Fi%3EM918T+Tumors&aulast=Robledo&aufirst=Mercedes&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-16-0947&rft.language%5B0%5D=eng
SOLR
_version_ 1792348155999682571
author Mancikova, Veronika, Montero-Conde, Cristina, Perales-Paton, Javier, Fernandez, Agustin, Santacana, María, Jodkowska, Karolina, Inglada-Pérez, Lucia, Castelblanco, Esmeralda, Borrego, Salud, Encinas, Mario, Matias-Guiu, Xavier, Fraga, Mario, Robledo, Mercedes
author_facet Mancikova, Veronika, Montero-Conde, Cristina, Perales-Paton, Javier, Fernandez, Agustin, Santacana, María, Jodkowska, Karolina, Inglada-Pérez, Lucia, Castelblanco, Esmeralda, Borrego, Salud, Encinas, Mario, Matias-Guiu, Xavier, Fraga, Mario, Robledo, Mercedes, Mancikova, Veronika, Montero-Conde, Cristina, Perales-Paton, Javier, Fernandez, Agustin, Santacana, María, Jodkowska, Karolina, Inglada-Pérez, Lucia, Castelblanco, Esmeralda, Borrego, Salud, Encinas, Mario, Matias-Guiu, Xavier, Fraga, Mario, Robledo, Mercedes
author_sort mancikova, veronika
container_issue 5
container_start_page 1334
container_title Clinical Cancer Research
container_volume 23
description <jats:title>Abstract</jats:title> <jats:p>Purpose: Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers, and the etiology specific to each known susceptibility mutation remains unknown. Exploiting multilayer genomic data, we focused our interest on the role of aberrant DNA methylation in MTC development.</jats:p> <jats:p>Experimental Design: We performed genome-wide DNA methylation profiling assessing more than 27,000 CpGs in the largest MTC series reported to date, comprising 48 molecularly characterized tumors. mRNA and miRNA expression data were available for 33 and 31 tumors, respectively. Two human MTC cell lines and 101 paraffin-embedded MTCs were used for validation.</jats:p> <jats:p>Results: The most distinctive methylome was observed for RETM918T-related tumors. Integration of methylation data with mRNA and miRNA expression data identified genes negatively regulated by promoter methylation. These in silico findings were confirmed in vitro for PLCB2, DKK4, MMP20, and miR-10a, -30a, and -200c. The mutation-specific aberrant methylation of PLCB2, DKK4, and MMP20 was validated in 25 independent MTCs by bisulfite pyrosequencing. The methylome and transcriptome data underscored JAK/Stat pathway involvement in RETM918T MTCs. Immunostaining [immunohistochemistry (IHC)] for the active form of signaling effector STAT3 was performed in a series of 101 MTCs. As expected, positive IHC was associated with RETM918T-bearing tumors (P &amp;lt; 0.02). Pharmacologic inhibition of STAT3 activity increased the sensitivity to vandetanib of the RETM918T-positive MTC cell line, MZ-CRC-1.</jats:p> <jats:p>Conclusions: Multilayer OMIC data analysis uncovered methylation hallmarks in genetically defined MTCs and revealed JAK/Stat signaling effector STAT3 as a potential therapeutic target for the treatment of RETM918T MTCs. Clin Cancer Res; 23(5); 1334–45. ©2016 AACR.</jats:p>
doi_str_mv 10.1158/1078-0432.ccr-16-0947
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE2LTA5NDc
imprint American Association for Cancer Research (AACR), 2017
imprint_str_mv American Association for Cancer Research (AACR), 2017
institution DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161
issn 1078-0432, 1557-3265
issn_str_mv 1078-0432, 1557-3265
language English
last_indexed 2024-03-01T18:06:42.099Z
match_str mancikova2017multilayeromicdatainmedullarythyroidcarcinomaidentifiesthestat3pathwayasapotentialtherapeutictargetinretm918ttumors
mega_collection American Association for Cancer Research (AACR) (CrossRef)
physical 1334-1345
publishDate 2017
publishDateSort 2017
publisher American Association for Cancer Research (AACR)
record_format ai
recordtype ai
series Clinical Cancer Research
source_id 49
spelling Mancikova, Veronika Montero-Conde, Cristina Perales-Paton, Javier Fernandez, Agustin Santacana, María Jodkowska, Karolina Inglada-Pérez, Lucia Castelblanco, Esmeralda Borrego, Salud Encinas, Mario Matias-Guiu, Xavier Fraga, Mario Robledo, Mercedes 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-16-0947 <jats:title>Abstract</jats:title> <jats:p>Purpose: Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers, and the etiology specific to each known susceptibility mutation remains unknown. Exploiting multilayer genomic data, we focused our interest on the role of aberrant DNA methylation in MTC development.</jats:p> <jats:p>Experimental Design: We performed genome-wide DNA methylation profiling assessing more than 27,000 CpGs in the largest MTC series reported to date, comprising 48 molecularly characterized tumors. mRNA and miRNA expression data were available for 33 and 31 tumors, respectively. Two human MTC cell lines and 101 paraffin-embedded MTCs were used for validation.</jats:p> <jats:p>Results: The most distinctive methylome was observed for RETM918T-related tumors. Integration of methylation data with mRNA and miRNA expression data identified genes negatively regulated by promoter methylation. These in silico findings were confirmed in vitro for PLCB2, DKK4, MMP20, and miR-10a, -30a, and -200c. The mutation-specific aberrant methylation of PLCB2, DKK4, and MMP20 was validated in 25 independent MTCs by bisulfite pyrosequencing. The methylome and transcriptome data underscored JAK/Stat pathway involvement in RETM918T MTCs. Immunostaining [immunohistochemistry (IHC)] for the active form of signaling effector STAT3 was performed in a series of 101 MTCs. As expected, positive IHC was associated with RETM918T-bearing tumors (P &amp;lt; 0.02). Pharmacologic inhibition of STAT3 activity increased the sensitivity to vandetanib of the RETM918T-positive MTC cell line, MZ-CRC-1.</jats:p> <jats:p>Conclusions: Multilayer OMIC data analysis uncovered methylation hallmarks in genetically defined MTCs and revealed JAK/Stat signaling effector STAT3 as a potential therapeutic target for the treatment of RETM918T MTCs. Clin Cancer Res; 23(5); 1334–45. ©2016 AACR.</jats:p> Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in <i>RET</i>M918T Tumors Clinical Cancer Research
spellingShingle Mancikova, Veronika, Montero-Conde, Cristina, Perales-Paton, Javier, Fernandez, Agustin, Santacana, María, Jodkowska, Karolina, Inglada-Pérez, Lucia, Castelblanco, Esmeralda, Borrego, Salud, Encinas, Mario, Matias-Guiu, Xavier, Fraga, Mario, Robledo, Mercedes, Clinical Cancer Research, Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors, Cancer Research, Oncology
title Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_full Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_fullStr Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_full_unstemmed Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_short Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
title_sort multilayer omic data in medullary thyroid carcinoma identifies the stat3 pathway as a potential therapeutic target in <i>ret</i>m918t tumors
title_unstemmed Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
topic Cancer Research, Oncology
url http://dx.doi.org/10.1158/1078-0432.ccr-16-0947